Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220514 · ClinicalTrials.gov registry record
Long-term Effects of COVID-19
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 71
- Enrollment target
NCT05220514: Completed study, sponsored by Mayo Clinic.
NCT05220514 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05220514 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients who were hospitalized with an acute neurological disease.
Primary Outcome
Collect participants' self reported response from questionnaire: Post-Covid Functional Status.
Interventions
- DRUG (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
- DRUG 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2024-11-30 |
What the finished NCT05220514 record still lists
NCT05220514 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195) is the first listed.
NCT05220514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05220514 about?
NCT05220514 is a clinical study titled "Long-term Effects of COVID-19". The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients who were hospitalized with an acute neurological disease.
What is the current status of trial NCT05220514?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2022-01-19. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT05220514?
The interventions under investigation include: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195) (DRUG), 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB) (DRUG).
Who is sponsoring clinical trial NCT05220514?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI